The ankylosing spondylitis and psoriatic arthritis markets are getting crowded, but Novartis now has long-term Cosentyx data that not all its rivals can boast.
With biologics dominating its pipeline, Sanofi will spend as much as $2 billion on its biologics manufacturing network over the next several years.
Amputations? Those are a problem specific to Johnson & Johnson's Invokana alone, the company's SGLT2 rivals contest.
The place to be in drug sales is biotech, at least if you're judging by pay. Biotech reps outearn pharma reps by almost $40,000 on average.
MannKind’s Afrezza is getting ready for a dose of reality. Reality TV, that is, as the lead sponsor of a diabetes reality show set to air in July.
Digital media giants will take to the south of France once again this weekend to woo pharma and healthcare marketers.
At the Cannes Lions Health festival this weekend, pharma's marketing gambles move into the spotlight.
New real-world analyses may make a case for using the SGLT2 drug class earlier in diabetes treatment, AstraZeneca’s execs suggest.
Creative types and marketing mavens come from all over the globe for the biggest advertising festival in the world—and for the first two days, it’s all about…
Merck said Monday night that it would pause enrollment on a pair of phase 3 Keytruda multiple myeloma studies to investigate patient deaths.